Skip to main content

Table 2 The status of FGFR1 gene amplification and protein overexpression in patients with hypopharyngeal and laryngeal squamous cell carcinoma

From: Prognostic implications of Fibroblast growth factor receptor 1 (FGFR1) gene amplification and protein overexpression in hypopharyngeal and laryngeal squamous cell carcinoma

Characteristics FGFR1 amplification, n = 66 P value FGFR1 high expression, n = 199 P value
Present, n (%) Absent, n (%) Present, n (%) Absent, n (%)
Total 8 (12.1) 58 (87.9)   21 (10.6) 178 (89.4)  
Primary sites    0.015    0.307
 Hypopharynx 6 (75.0) 36 (62.1)   6 (28.6) 47 (26.4)  
 Larynx 2 (25.0) 22 (37.9)   15 (71.4) 131 (73.6)  
Gender    0.771    0.145
 Female 0 (0.0) 2 (3.4)   3 (14.3) 10 (5.6)  
 Male 8 (100.0) 56 (96.6)   18 (85.7) 168 (94.4)  
Age (years)    0.452    0.820
 Median (range) 68.0 (55–73) 63.0 (42–88)   63.0 (45–78) 64.0 (30–88)  
 < 65 3 (37.5) 33 (56.9)   12 (57.1) 95 (53.4)  
 ≥ 65 5 (62.5) 25 (43.1)   9 (42.9) 83 (46.6)  
Smoking    0.405    0.302
 Never smoker 2 (25.0) 7 (12.1)   3 (14.3) 19 (10.7)  
 Former smoker 1 (12.5) 15 (25.9)   6 (28.6) 45 (25.3)  
 Current smoker 5 (62.5) 36 (62.1)   12 (57.1) 114 (64.0)  
Alcohol    0.196    0.778
 Non- or social- drinker 0 (0.0) 13 (22.4)   5 (23.8) 37 (20.8)  
 Heavy drinker 8 (100.0) 45 (77.6)   16 (76.2) 141 (79.2)  
p16 status    0.551    0.697
 Negative 7 (87.5) 47 (81.0)   14 (82.4) 131 (88.5)  
 Positive 1 (12.5) 11 (19.0)   3 (17.6) 17 (11.5)  
 Unknown      
Histologic differentiation    0.355    <  0.001
 Well differentiated 2 (25.0) 15 (25.9)   1 (4.8) 58 (32.6)  
 Moderately differentiated 4 (50.0) 37 (63.8)   11 (52.4) 108 (60.7)  
 Poorly differentiated 2 (25.0) 6 (10.3)   9 (42.9) 12 (6.7)  
Lymphovascular invasion    0.031    0.096
 Absent 4 (50.0) 50 (86.2)   13 (61.9) 141 (79.2)  
 Present 4 (50.0) 8 (13.8)   8 (38.1) 37 (20.8)  
Perineural invasion    0.614    0.335
 Absent 7 (87.5) 52 (89.7)   16 (76.2) 152 (85.4)  
 Present 1 (12.5) 6 (10.3)   5 (23.8) 26 (14.6)  
Positive resection margin    0.537    0.494
 Absent 4 (50.0) 32 (55.2)   16 (76.2) 130 (73.0)  
 Present 4 (50.0) 26 (44.8)   5 (23.8) 48 (27.0)  
Pathological T-classification    0.365    0.238
 pT1 3 (37.5) 29 (50.0)   4 (19.0) 59 (33.1)  
 pT2 4 (50.0) 18 (31.0)   9 (42.9) 49 (27.5)  
 pT3 0 (0.0) 10 (17.2)   4 (19.0) 48 (27.0)  
 pT4a 1 (9.1) 1 (1.7)   4 (19.0) 22 (12.4)  
Pathological N-classification    0.012    0.003
 pN0 3 (27.3) 32 (58.2)   6 (28.6) 105 (59.0)  
 pN1 0 (0.0) 4 (7.3)   1 (4.8) 12 (6.7)  
 pN2 1 (9.1) 7 (12.7)   4 (19.0) 22 (12.4)  
 pN3 7 (63.6) 12 (21.8)   10 (47.6) 39 (21.9)  
Pathological stage    0.047    0.001
 Stage I 2 (25.0) 24 (41.4)   1 (4.8) 53 (29.8)  
 Stage II 0 (0.0) 5 (8.6)   3 (14.3) 26 (14.6)  
 Stage III 0 (0.0) 7 (12.1)   2 (9.5) 30 (16.9)  
 Stage IVA 1 (12.5) 8 (13.8)   5 (23.8) 30 (16.9)  
 Stage IVB 5 (62.5) 14 (24.1)   10 (47.6) 39 (21.9)  
Recurrence    0.042    0.263
 No 4 (50.0) 49 (84.5)   14 (66.7) 141 (79.2)  
 Yes 4 (50.0) 9 (15.5)   7 (33.3) 37 (20.8)  
 Local recurrence only 2 (50.0) 5 (55.6)   2 (28.6) 20 (54.1)  
 Distant recurrence 2 (50.0) 4 (44.4)   5 (71.4) 17 (45.9)